Un treball on participa el Dr. Iván Castellví, del Servei de Medicina Interna de Sant Pau, “Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series” ha sortit recentment publicat a Annals of the Rheumatic Diseases,  una de les revistes de més impacte en el camp de la reumatologia i les malalties autoimmunes.

“Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series”